Molecular biomarker set for early detection of ovarian cancer

• US 9,057,107 B2
• Filed: 03/08/2012
• Issued: 06/16/2015
• Est. Priority Date: 03/08/2011
• Status: Active Grant

• Current Assignee: King Abdullah University of Science and Technology
• Original Assignee: King Abdullah University of Science and Technology
• Inventors: Bajic, Vladimir, Kaur, Mandeep
• Primary Examiner(s): Yu, Misook
• Assistant Examiner(s): WU, JULIE ZHEN QIN
• Application Number:
  US13/415,004
• Publication Number:
  US 20120231090A1
• Time in Patent Office: 1,195 Days
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/57449 of ovaries
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

Claims

1. A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, consisting of the steps:

a) obtaining nucleic acids from a sample from the individual suspected of having ovarian cancer;

b) detecting the expression level of TFAP2A from the sample from the individual with the expression level of TFAP2A from a control, and

c) detecting the expression level of CA125 and E2F5 from the sample from the individual with the expression level of CA125 and E2F5 from a control.

20. The method of claim 1, wherein the sample is ovarian tissue, blood, serum, or plasma.

2. A method of identifying ovarian cancer in an individual or the risk of developing ovarian cancer in an individual, consisting of the step of detecting the expression level of TFAP2A, CA125 and E2F5 from the individual suspected of having ovarian cancer and the expression level of TFAP2A, CA125 and E2F5 from a control.

3. The method of claim 2, wherein the protein level of TFAP2A, CA125, and E2F5 from the individual is determined.

4. The method of claim 3, wherein the protein level of TFAP2A, CA125, and E2F5 is determined from the blood of the individual.

5. The method of claim 3, wherein the protein level of TFAP2A, CA125, and E2F5 is determined with an antibody.

6. The method of claim 5, wherein the antibody is a monoclonal antibody.

7. The method of claim 2, wherein the mRNA level of TFAP2A, CA125, and E2F5 from the individual is determined.

8. The method of claim 7, wherein the mRNA level of TFAP2A is determined from ovarian tissue or blood from the individual.

9. The method of claim 7, wherein the mRNA level is determined by microarray, Northern, or RT-PCR.

10. The method of claim 2, wherein the control is tissue or blood from one or more normal individuals or is from tissue or blood from the individual.

11. The method of claim 2, wherein the method detects the stage of ovarian cancer in the individual.

12. The method of claim 2, wherein the method further comprises a step of detecting the stage of ovarian cancer in the individual.

13. The method of claim 11, wherein the stage is stage IA, IC, IIIC, or a combination thereof.

14. The method of claim 2, further comprising the step of performing an additional ovarian cancer detection method.

15. The method of claim 14, wherein the additional ovarian cancer detection method is selected from the group consisting of palpitation, ultrasound, magnetic resonance imaging, X-ray, CT scan, blood testing, and biopsy.

16. The method of claim 2, further comprising the step of administering treatment for ovarian cancer.

17. The method of claim 2, further comprising the step of obtaining a sample from the individual.

18. The method of claim 2, further comprising the step of isolating TFAP2A protein and/or mRNA from the sample.

19. The method of claim 2, further comprising the steps of obtaining a sample from the individual and isolating TFAP2A protein and/or mRNA from the sample.